MicroRNA expression profiles of head and neck squamous cell carcinoma with docetaxel-induced multidrug resistance
Background The purpose of this study was to investigate the potential role of variable microRNA (miRNA) expression in the development of multidrug resistance (MDR) in head and neck cancer. Methods Head and neck squamous cell carcinoma cell lines UMSCC‐1 and SQ20B were treated with docetaxel at incre...
Saved in:
Published in | Head & neck Vol. 33; no. 6; pp. 786 - 791 |
---|---|
Main Authors | , , , , , |
Format | Journal Article |
Language | English |
Published |
Hoboken
Wiley Subscription Services, Inc., A Wiley Company
01.06.2011
Wiley |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | Background
The purpose of this study was to investigate the potential role of variable microRNA (miRNA) expression in the development of multidrug resistance (MDR) in head and neck cancer.
Methods
Head and neck squamous cell carcinoma cell lines UMSCC‐1 and SQ20B were treated with docetaxel at increasing concentrations to develop resistant cell lines. Parental and resistant cells were treated with cisplatin, 5‐fluorouracil, paclitaxel, methotrexate, and doxorubicin to confirm cross‐resistance. The miRNA pattern of resistant cells was then compared with their parental cells.
Results
Docetaxel treatment successfully induced resistance primarily and induced multidrug cross‐resistance. Resistant cells showed significant downregulation of miR‐100, miR‐130a, and miR‐197 and upregulation in miR‐101, miR‐181b, miR‐181d, and miR‐195 expression when compared with their parent cells (p < .01). Real‐time polymerase chain reaction (PCR) analysis confirmed statistically significant downregulation in miR‐100 and miR‐130a and upregulation in miR‐181d expression (p < .001).
Conclusion
Alterations in miRNA expression has direct relationship to MDR in head and neck cancer and may serve as biomolecular targets for reversal of MDR. © 2010 Wiley Periodicals, Inc. Head Neck, 2011 |
---|---|
AbstractList | Background The purpose of this study was to investigate the potential role of variable microRNA (miRNA) expression in the development of multidrug resistance (MDR) in head and neck cancer. Methods Head and neck squamous cell carcinoma cell lines UMSCC-1 and SQ20B were treated with docetaxel at increasing concentrations to develop resistant cell lines. Parental and resistant cells were treated with cisplatin, 5-fluorouracil, paclitaxel, methotrexate, and doxorubicin to confirm cross-resistance. The miRNA pattern of resistant cells was then compared with their parental cells. Results Docetaxel treatment successfully induced resistance primarily and induced multidrug cross-resistance. Resistant cells showed significant downregulation of miR-100, miR-130a, and miR-197 and upregulation in miR-101, miR-181b, miR-181d, and miR-195 expression when compared with their parent cells (p < .01). Real-time polymerase chain reaction (PCR) analysis confirmed statistically significant downregulation in miR-100 and miR-130a and upregulation in miR-181d expression (p < .001). Conclusion Alterations in miRNA expression has direct relationship to MDR in head and neck cancer and may serve as biomolecular targets for reversal of MDR. [copy 2010 Wiley Periodicals, Inc. Head Neck, 2011 BACKGROUNDThe purpose of this study was to investigate the potential role of variable microRNA (miRNA) expression in the development of multidrug resistance (MDR) in head and neck cancer.METHODSHead and neck squamous cell carcinoma cell lines UMSCC-1 and SQ20B were treated with docetaxel at increasing concentrations to develop resistant cell lines. Parental and resistant cells were treated with cisplatin, 5-fluorouracil, paclitaxel, methotrexate, and doxorubicin to confirm cross-resistance. The miRNA pattern of resistant cells was then compared with their parental cells.RESULTSDocetaxel treatment successfully induced resistance primarily and induced multidrug cross-resistance. Resistant cells showed significant downregulation of miR-100, miR-130a, and miR-197 and upregulation in miR-101, miR-181b, miR-181d, and miR-195 expression when compared with their parent cells (p < .01). Real-time polymerase chain reaction (PCR) analysis confirmed statistically significant downregulation in miR-100 and miR-130a and upregulation in miR-181d expression (p < .001).CONCLUSIONAlterations in miRNA expression has direct relationship to MDR in head and neck cancer and may serve as biomolecular targets for reversal of MDR. Abstract Background The purpose of this study was to investigate the potential role of variable microRNA (miRNA) expression in the development of multidrug resistance (MDR) in head and neck cancer. Methods Head and neck squamous cell carcinoma cell lines UMSCC‐1 and SQ20B were treated with docetaxel at increasing concentrations to develop resistant cell lines. Parental and resistant cells were treated with cisplatin, 5‐fluorouracil, paclitaxel, methotrexate, and doxorubicin to confirm cross‐resistance. The miRNA pattern of resistant cells was then compared with their parental cells. Results Docetaxel treatment successfully induced resistance primarily and induced multidrug cross‐resistance. Resistant cells showed significant downregulation of miR‐100, miR‐130a, and miR‐197 and upregulation in miR‐101, miR‐181b, miR‐181d, and miR‐195 expression when compared with their parent cells ( p < .01). Real‐time polymerase chain reaction (PCR) analysis confirmed statistically significant downregulation in miR‐100 and miR‐130a and upregulation in miR‐181d expression ( p < .001). Conclusion Alterations in miRNA expression has direct relationship to MDR in head and neck cancer and may serve as biomolecular targets for reversal of MDR. © 2010 Wiley Periodicals, Inc. Head Neck, 2011 The purpose of this study was to investigate the potential role of variable microRNA (miRNA) expression in the development of multidrug resistance (MDR) in head and neck cancer. Head and neck squamous cell carcinoma cell lines UMSCC-1 and SQ20B were treated with docetaxel at increasing concentrations to develop resistant cell lines. Parental and resistant cells were treated with cisplatin, 5-fluorouracil, paclitaxel, methotrexate, and doxorubicin to confirm cross-resistance. The miRNA pattern of resistant cells was then compared with their parental cells. Docetaxel treatment successfully induced resistance primarily and induced multidrug cross-resistance. Resistant cells showed significant downregulation of miR-100, miR-130a, and miR-197 and upregulation in miR-101, miR-181b, miR-181d, and miR-195 expression when compared with their parent cells (p < .01). Real-time polymerase chain reaction (PCR) analysis confirmed statistically significant downregulation in miR-100 and miR-130a and upregulation in miR-181d expression (p < .001). Alterations in miRNA expression has direct relationship to MDR in head and neck cancer and may serve as biomolecular targets for reversal of MDR. Background The purpose of this study was to investigate the potential role of variable microRNA (miRNA) expression in the development of multidrug resistance (MDR) in head and neck cancer. Methods Head and neck squamous cell carcinoma cell lines UMSCC‐1 and SQ20B were treated with docetaxel at increasing concentrations to develop resistant cell lines. Parental and resistant cells were treated with cisplatin, 5‐fluorouracil, paclitaxel, methotrexate, and doxorubicin to confirm cross‐resistance. The miRNA pattern of resistant cells was then compared with their parental cells. Results Docetaxel treatment successfully induced resistance primarily and induced multidrug cross‐resistance. Resistant cells showed significant downregulation of miR‐100, miR‐130a, and miR‐197 and upregulation in miR‐101, miR‐181b, miR‐181d, and miR‐195 expression when compared with their parent cells (p < .01). Real‐time polymerase chain reaction (PCR) analysis confirmed statistically significant downregulation in miR‐100 and miR‐130a and upregulation in miR‐181d expression (p < .001). Conclusion Alterations in miRNA expression has direct relationship to MDR in head and neck cancer and may serve as biomolecular targets for reversal of MDR. © 2010 Wiley Periodicals, Inc. Head Neck, 2011 |
Author | Dai, Yuemeng Fan, Chun-Yang Xie, Cheng-hui Spring, Paul M. Neis, John P. Vural, Emre |
Author_xml | – sequence: 1 givenname: Yuemeng surname: Dai fullname: Dai, Yuemeng organization: Department of Otolaryngology-Head and Neck Surgery, University of Arkansas for Medical Sciences, Little Rock, Arkansas – sequence: 2 givenname: Cheng-hui surname: Xie fullname: Xie, Cheng-hui organization: Department of Pathology, University of Arkansas for Medical Sciences, Little Rock, Arkansas – sequence: 3 givenname: John P. surname: Neis fullname: Neis, John P. organization: Department of Otolaryngology-Head and Neck Surgery, University of Arkansas for Medical Sciences, Little Rock, Arkansas – sequence: 4 givenname: Chun-Yang surname: Fan fullname: Fan, Chun-Yang organization: Department of Pathology, University of Arkansas for Medical Sciences, Little Rock, Arkansas – sequence: 5 givenname: Emre surname: Vural fullname: Vural, Emre email: VuralEmreA@uams.edu organization: Department of Otolaryngology-Head and Neck Surgery, University of Arkansas for Medical Sciences, Little Rock, Arkansas – sequence: 6 givenname: Paul M. surname: Spring fullname: Spring, Paul M. organization: Department of Otolaryngology-Head and Neck Surgery, University of Arkansas for Medical Sciences, Little Rock, Arkansas |
BackLink | http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=24181023$$DView record in Pascal Francis https://www.ncbi.nlm.nih.gov/pubmed/21560177$$D View this record in MEDLINE/PubMed |
BookMark | eNp9kUtv1DAUhS1URB-w4A8gbxBlkdaOHTtZltJOQaWIl0BsLMe-ZkwTZ8ZO1Om_x8PMwApWvrK--zjnHKK9MARA6CklJ5SQ8nQO9qSkFScP0AEljSwI43JvXXNWMCL5PjpM6SchhAlePkL7GRaESnmAlu-8icPHmzMMq0WElPwQ8CIOzneQ8ODwHLTFOlgcwNzitJx0P0wJG-g6bHQ0Pgy9xnd-nGM7GBj1CrrCBzsZsLifutHbOP3AebRPow4GHqOHTncJnmzfI_Tl8uLz-VVx_X725vzsujC8rEjRGEKEsw1AVVYArqWmMjTfz2StWya1a4Xg3Lq6ZC3TunZ0rUiIpqYNMzU7Qi82c7Oa5QRpVL1P67N1gKxA1ULkPYTSTB7_l6Rc1KxiFeUZfblBs2kpRXBqEX2v472iRK2zUDkL9TuLzD7bjp3aPv_uyJ35GXi-BXQyunMx2-PTX47TmpKSZe50w93lUO7_vVFdXbzerS42HdlzWP3p0PFWCclkpb7ezNTs1Tfy4VP9Xb1lvwCdGrFK |
CitedBy_id | crossref_primary_10_1016_j_molcel_2014_05_005 crossref_primary_10_3892_ol_2016_4892 crossref_primary_10_3892_or_2012_2155 crossref_primary_10_1016_j_mtadv_2023_100407 crossref_primary_10_3892_mmr_2017_6173 crossref_primary_10_1016_j_oraloncology_2020_105002 crossref_primary_10_1186_s13046_016_0296_0 crossref_primary_10_1093_abbs_gmt113 crossref_primary_10_1038_s41598_018_35799_1 crossref_primary_10_1038_s41392_020_00419_w crossref_primary_10_1155_2015_186904 crossref_primary_10_1016_j_oraloncology_2020_104916 crossref_primary_10_18632_oncotarget_21235 crossref_primary_10_3390_ijms21072619 crossref_primary_10_1371_journal_pone_0117809 crossref_primary_10_1371_journal_pone_0051436 crossref_primary_10_1021_mp200255d crossref_primary_10_1371_journal_pone_0107467 crossref_primary_10_1016_j_mrrev_2023_108467 crossref_primary_10_1016_j_gene_2016_06_035 crossref_primary_10_1111_jcmm_12131 crossref_primary_10_1016_j_jid_2021_01_028 crossref_primary_10_1007_s10238_022_00849_6 crossref_primary_10_1016_j_molonc_2013_12_011 crossref_primary_10_1177_0022034511431261 crossref_primary_10_1038_cddis_2013_548 crossref_primary_10_1038_mt_2015_10 crossref_primary_10_1002_pros_23031 crossref_primary_10_1007_s13277_014_2520_x crossref_primary_10_1038_oncsis_2013_3 crossref_primary_10_1111_j_1600_0714_2011_01121_x crossref_primary_10_1186_1746_1596_7_159 crossref_primary_10_1016_j_canep_2018_12_008 crossref_primary_10_3892_or_2013_2532 crossref_primary_10_1007_s10555_016_9625_1 crossref_primary_10_1177_1010428317698379 crossref_primary_10_1016_j_tjog_2014_06_007 crossref_primary_10_18632_oncotarget_1776 crossref_primary_10_5339_jlghs_2014_1 crossref_primary_10_1038_onc_2012_28 crossref_primary_10_1002_cac2_12138 crossref_primary_10_1016_j_addr_2015_05_001 crossref_primary_10_1016_j_ejca_2011_04_037 crossref_primary_10_1002_hed_26533 crossref_primary_10_1016_j_critrevonc_2013_07_012 crossref_primary_10_1007_s12094_015_1318_7 crossref_primary_10_3390_jpm12091436 crossref_primary_10_1016_j_molonc_2015_10_004 crossref_primary_10_1016_j_canlet_2011_11_024 crossref_primary_10_1124_pr_111_005637 crossref_primary_10_3892_mmr_2017_6233 crossref_primary_10_1016_j_ctrv_2012_07_005 crossref_primary_10_1016_j_prp_2023_154949 crossref_primary_10_1093_bib_bbs082 |
Cites_doi | 10.1261/rna.2183803 10.2174/1381612043453117 10.2174/1568009054863609 10.1126/science.1064921 10.4161/cbt.5.5.2655 10.1016/S0304-3835(99)00263-3 10.1038/sj.onc.1210681 10.1159/000086183 10.1056/NEJMra001375 10.1016/j.ccr.2006.01.025 10.1038/sj.bjc.6600685 10.1016/j.bcp.2008.06.007 10.1074/jbc.270.52.31269 10.3322/canjclin.55.2.74 10.1002/cncr.11063 10.1146/annurev.biochem.71.102301.093055 10.1128/MCB.22.6.1844-1857.2002 10.1073/pnas.0509603102 10.1002/1097-0215(200102)9999:9999<::AID-IJC1180>3.0.CO;2-T 10.1002/ijc.23501 10.2174/1568011053765967 10.1007/BF00744663 10.1158/0008-5472.CAN-07-2488 10.1016/j.ctrv.2008.03.002 10.1016/0065-2571(94)90025-6 10.1038/nrc706 10.1093/oxfordjournals.annonc.a058903 10.1158/0008-5472.CAN-05-1783 |
ContentType | Journal Article |
Copyright | Copyright © 2010 Wiley Periodicals, Inc. 2015 INIST-CNRS |
Copyright_xml | – notice: Copyright © 2010 Wiley Periodicals, Inc. – notice: 2015 INIST-CNRS |
DBID | BSCLL IQODW CGR CUY CVF ECM EIF NPM AAYXX CITATION 7TM 7X8 |
DOI | 10.1002/hed.21540 |
DatabaseName | Istex Pascal-Francis Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed CrossRef Nucleic Acids Abstracts MEDLINE - Academic |
DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) CrossRef Nucleic Acids Abstracts MEDLINE - Academic |
DatabaseTitleList | Nucleic Acids Abstracts MEDLINE - Academic CrossRef MEDLINE |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
EISSN | 1097-0347 |
EndPage | 791 |
ExternalDocumentID | 10_1002_hed_21540 21560177 24181023 HED21540 ark_67375_WNG_GBX0QS8Z_J |
Genre | article Research Support, U.S. Gov't, Non-P.H.S Journal Article |
GrantInformation_xml | – fundername: Veterans Administration Advanced Research Career Development Award (PMS) |
GroupedDBID | --- .3N .55 .GA .Y3 05W 0R~ 10A 1L6 1OB 1OC 1ZS 31~ 33P 36B 3O- 3SF 3WU 4.4 4ZD 50Y 50Z 51W 51X 52M 52N 52O 52P 52R 52S 52T 52U 52V 52W 52X 53G 5GY 5VS 66C 702 7PT 8-0 8-1 8-3 8-4 8-5 8UM 930 A01 A03 AAESR AAEVG AAHHS AANLZ AAONW AASGY AAXRX AAZKR ABCQN ABCUV ABEML ABIJN ABQWH ABXGK ACAHQ ACBWZ ACCFJ ACCZN ACGFS ACGOF ACMXC ACPOU ACPRK ACSCC ACXBN ACXQS ADBBV ADBTR ADEOM ADIZJ ADKYN ADMGS ADOZA ADZMN ADZOD AEEZP AEIGN AEIMD AEQDE AEUQT AEUYR AFBPY AFFPM AFGKR AFPWT AFZJQ AHBTC AHMBA AIACR AITYG AIURR AIWBW AJBDE ALAGY ALMA_UNASSIGNED_HOLDINGS ALUQN AMBMR AMYDB ASPBG ATUGU AVWKF AZBYB AZFZN AZVAB BAFTC BDRZF BFHJK BHBCM BROTX BRXPI BSCLL BY8 C45 CS3 D-6 D-7 D-E D-F DCZOG DPXWK DR2 DRFUL DRMAN DRSTM DUUFO EBD EBS EJD EMB EMOBN F00 F01 F04 F5P FEDTE G-S G.N GNP GODZA H.X HBH HF~ HGLYW HHY HHZ HVGLF HZ~ IX1 J0M JPC KBYEO KQQ LATKE LAW LC2 LC3 LEEKS LH4 LITHE LOXES LP6 LP7 LUTES LW6 LYRES M6P MEWTI MK4 MRFUL MRMAN MRSTM MSFUL MSMAN MSSTM MXFUL MXMAN MXSTM N04 N05 N9A NF~ NNB O66 O9- OIG OVD P2W P2X P2Z P4B P4D PALCI PQQKQ Q.N Q11 QB0 QRW R.K RIWAO ROL RWI RX1 RYL SAMSI SUPJJ SV3 TEORI UB1 V2E W8V W99 WBKPD WH7 WHWMO WIH WIJ WIK WJL WOHZO WQJ WRC WUP WVDHM WWO WXI WXSBR X7M XG1 XPP XV2 ZGI ZXP ZZTAW ~IA ~WT AAUGY AAVGM ABHUG ACXME ADAWD ADDAD AFVGU AGJLS IQODW CGR CUY CVF ECM EIF NPM AAYXX CITATION 7TM 7X8 |
ID | FETCH-LOGICAL-c4250-9c006fd9ee525eefb1c5c1364378ab37afb6644df823b3aa8f101776698193c83 |
IEDL.DBID | DR2 |
ISSN | 1043-3074 1097-0347 |
IngestDate | Sat Aug 17 01:54:34 EDT 2024 Sat Aug 17 01:12:58 EDT 2024 Fri Aug 23 05:02:57 EDT 2024 Sat Sep 28 08:34:04 EDT 2024 Sun Oct 22 16:05:00 EDT 2023 Sat Aug 24 00:57:00 EDT 2024 Wed Oct 30 09:52:40 EDT 2024 |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 6 |
Keywords | Antineoplastic agent multidrug resistance RNA Stomatology Docetaxel ENT Malignant tumor Profile Resistance Taxane derivatives Head and neck ENT disease Head and neck cancer Head and neck squamous cell carcinoma Antimitotic micro-RNA Cancer |
Language | English |
License | CC BY 4.0 Copyright © 2010 Wiley Periodicals, Inc. |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c4250-9c006fd9ee525eefb1c5c1364378ab37afb6644df823b3aa8f101776698193c83 |
Notes | ArticleID:HED21540 istex:7ED381CA2930F15B0C591AA22FC4D26895261753 ark:/67375/WNG-GBX0QS8Z-J Veterans Administration Advanced Research Career Development Award (PMS) ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-1 content type line 23 ObjectType-Article-1 ObjectType-Feature-2 |
PMID | 21560177 |
PQID | 1468353514 |
PQPubID | 23462 |
PageCount | 6 |
ParticipantIDs | proquest_miscellaneous_866250011 proquest_miscellaneous_1468353514 crossref_primary_10_1002_hed_21540 pubmed_primary_21560177 pascalfrancis_primary_24181023 wiley_primary_10_1002_hed_21540_HED21540 istex_primary_ark_67375_WNG_GBX0QS8Z_J |
PublicationCentury | 2000 |
PublicationDate | June 2011 |
PublicationDateYYYYMMDD | 2011-06-01 |
PublicationDate_xml | – month: 06 year: 2011 text: June 2011 |
PublicationDecade | 2010 |
PublicationPlace | Hoboken |
PublicationPlace_xml | – name: Hoboken – name: Hoboken, NJ – name: United States |
PublicationTitle | Head & neck |
PublicationTitleAlternate | Head Neck |
PublicationYear | 2011 |
Publisher | Wiley Subscription Services, Inc., A Wiley Company Wiley |
Publisher_xml | – name: Wiley Subscription Services, Inc., A Wiley Company – name: Wiley |
References | El-Osta A, Kantharidis P, Zalcberg JR, Wolffe AP. Precipitous release of methyl-CpG binding protein 2 and histone deacetylase 1 from the methylated human multidrug resistance gene (MDR1) on activation. Mol Cell Biol 2002; 22: 1844-1857. Luqmani YA. Mechanisms of drug resistance in cancer chemotherapy. Med Princ Pract 2005; 14 Suppl 1: 35-48. Iorio MV, Ferracin M, Liu CG, et al. MicroRNA gene expression deregulation in human breast cancer. Cancer Res 2005; 65: 7065-7070. Sorokin A. Cyclooxygenase-2: potential role in regulation of drug efflux and multidrug resistance phenotype. Curr Pharm Des 2004; 10: 647-657. Yang H, Kong W, He L, et al. MicroRNA expression profiling in human ovarian cancer: miR-214 induces cell survival and cisplatin resistance by targeting PTEN. Cancer Res 2008; 68: 425-433. Haber M, Burkhart CA, Regl DL, Madafiglio J, Norris MD, Horwitz SB. Altered expression of M beta 2, the class II beta-tubulin isotype, in a murine J774.2 cell line with a high level of taxol resistance. J Biol Chem 1995; 270: 31269-31275. Mizumachi T, Suzuki S, Naito A, et al. Increased mitochondrial DNA induces acquired docetaxel resistance in head and neck cancer cells. Oncogene 2008; 27: 831-838. Lokich J. Infusional 5-FU: historical evolution, rationale, and clinical experience. Oncology (Williston Park) 1998; 12( 10 Suppl 7): 19-22. Gottesman MM, Fojo T, Bates SE. Multidrug resistance in cancer: role of ATP-dependent transporters. Nat Rev Cancer 2002; 2: 48-58. Dey S, Spring PM, Amold S, et al. Low-dose fractionated radiation potentiates the effects of paclitaxel in wild-type and mutant p53 head and neck tumor cell lines. Clin Cancer Res 2003; 9: 1557-1565. Huennekens FM. The methotrexate story: a paradigm for development of cancer chemotherapeutic agents. Adv Enzyme Regul 1994; 34: 397-419. Posner MR, Lefebvre JL. Docetaxel induction therapy in locally advanced squamous cell carcinoma of the head and neck. Br J Cancer 2003; 88: 11-17. Xia L, Zhang D, Du R, et al. miR-15b and miR-16 modulate multidrug resistance by targeting BCL2 in human gastric cancer cells. Int J Cancer 2008; 123: 372-379. Moscow JA, Dixon KH. Glutathione-related enzymes, glutathione and multidrug resistance. Cytotechnology 1993; 12: 155-170. Momparler RL, Karon M, Siegel SE, Avila F. Effect of adriamycin on DNA, RNA and protein synthesis in cell-free systems and intact cells. Cancer Res 1976; 36: 2891-2895. Zhu B, Liu GT, Zhao YM, Wu RS, Strada SJ. Chemosensitizing multiple drug resistance of human carcinoma by Bicyclol involves attenuated p-glycoprotein, GST-P and Bcl-2. Cancer Biol Ther 2006; 5: 536-543. Schöndorf T, Scharl A, Kurbacher CM, et al. Amplification of the mdr1-gene is uncommon in recurrent ovarian carcinomas. Cancer Lett 1999; 146: 195-199. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005; 55: 74-108. Meijerman I, Beijnen JH, Schellens JH. Combined action and regulation of phase II enzymes and multidrug resistance proteins in multidrug resistance in cancer. Cancer Treat Rev 2008; 34: 505-520. Haddad R, Colevas AD, Tishler R, et al. Docetaxel, cisplatin, and 5-fluorouracil-based induction chemotherapy in patients with locally advanced squamous cell carcinoma of the head and neck: the Dana Farber Cancer Institute experience. Cancer 2003; 97: 412-418. Sedletska Y, Giraud-Panis MJ, Malinge JM. Cisplatin is a DNA-damaging antitumour compound triggering multifactorial biochemical responses in cancer cells: importance of apoptotic pathways. Curr Med Chem Anticancer Agents 2005; 5: 251-265. He H, Jazdzewski K, Li W, et al. The role of microRNA genes in papillary thyroid carcinoma. Proc Natl Acad Sci U S A 2005; 102: 19075-19080. Lagos-Quintana M, Rauhut R, Landeckel W, Tuschl T. Identification of novel genes coding for small expressed RNAs. Science 2001; 294: 853-858. Zhu H, Wu H, Liu X, et al. Role of microRNA miR-27a and miR-451 in the regulation of MDR1/P-glycoprotein expression in human cancer cells. Biochem Pharmacol 2008; 76: 582-588. Uematsu T, Hasegawa T, Hiraoka BY, et al. Multidrug resistance gene 1 expression in salivary gland adenocarcinomas and oral squamous-cell carcinomas. Int J Cancer 2001; 92: 187-194. Forastiere A, Koch W, Trotti A, Sidransky D. Head and neck cancer. N Engl J Med 2001; 345: 1890-1900. Yanaihara N, Caplen N, Bowman E, et al. Unique microRNA molecular profiles in lung cancer diagnosis and prognosis. Cancer Cell 2006; 9: 189-198. Verweij J, Clavel M, Chevalier B. Paclitaxel (Taxol) and docetaxel (Taxotere): not simply two of a kind. Ann Oncol 1994; 5: 495-505. Gottesman MM. How cancer cells evade chemotherapy: sixteenth Richard and Hinda Rosenthal Foundation Award Lecture. Cancer Res 1993; 53: 747-754. Borst P, Elferink RO. Mammalian ABC transporters in health and disease. Annu Rev Biochem 2002; 71: 537-592. Mahadevan D, Shirahatti N. Strategies for targeting the multidrug resistance-1 (MDR1)/P-gp transporter in human malignancies. Curr Cancer Drug Targets 2005; 5: 445-455. Ambros V, Bartel B, Bartel DP, et al. A uniform system for microRNA annotation. RNA 2003; 9: 277-279. 2001; 92 2006; 9 2002; 2 2008; 34 2006; 5 2005; 65 1999; 146 2008; 76 2008; 123 2003; 97 2001; 345 1995; 270 2004; 10 1993; 12 2001; 294 1976; 36 2005; 102 1993; 53 2008; 27 2002; 22 2003; 9 1994; 34 2005; 5 2008; 68 2002; 71 2005; 55 1994; 5 1998; 12 2003; 88 2005; 14 e_1_2_6_31_2 e_1_2_6_30_2 e_1_2_6_18_2 Momparler RL (e_1_2_6_23_2) 1976; 36 e_1_2_6_19_2 Dey S (e_1_2_6_14_2) 2003; 9 e_1_2_6_12_2 e_1_2_6_13_2 e_1_2_6_10_2 e_1_2_6_33_2 e_1_2_6_11_2 e_1_2_6_32_2 e_1_2_6_16_2 e_1_2_6_17_2 e_1_2_6_15_2 e_1_2_6_20_2 Lokich J (e_1_2_6_24_2) 1998; 12 e_1_2_6_8_2 e_1_2_6_7_2 e_1_2_6_9_2 e_1_2_6_29_2 e_1_2_6_4_2 e_1_2_6_3_2 e_1_2_6_6_2 e_1_2_6_5_2 Gottesman MM (e_1_2_6_22_2) 1993; 53 e_1_2_6_2_2 e_1_2_6_21_2 e_1_2_6_28_2 e_1_2_6_27_2 e_1_2_6_26_2 e_1_2_6_25_2 |
References_xml | – volume: 10 start-page: 647 year: 2004 end-page: 657 article-title: Cyclooxygenase‐2: potential role in regulation of drug efflux and multidrug resistance phenotype publication-title: Curr Pharm Des – volume: 294 start-page: 853 year: 2001 end-page: 858 article-title: Identification of novel genes coding for small expressed RNAs publication-title: Science – volume: 5 start-page: 445 year: 2005 end-page: 455 article-title: Strategies for targeting the multidrug resistance‐1 (MDR1)/P‐gp transporter in human malignancies publication-title: Curr Cancer Drug Targets – volume: 9 start-page: 277 year: 2003 end-page: 279 article-title: A uniform system for microRNA annotation publication-title: RNA – volume: 65 start-page: 7065 year: 2005 end-page: 7070 article-title: MicroRNA gene expression deregulation in human breast cancer publication-title: Cancer Res – volume: 92 start-page: 187 year: 2001 end-page: 194 article-title: Multidrug resistance gene 1 expression in salivary gland adenocarcinomas and oral squamous‐cell carcinomas publication-title: Int J Cancer – volume: 27 start-page: 831 year: 2008 end-page: 838 article-title: Increased mitochondrial DNA induces acquired docetaxel resistance in head and neck cancer cells publication-title: Oncogene – volume: 97 start-page: 412 year: 2003 end-page: 418 article-title: Docetaxel, cisplatin, and 5‐fluorouracil‐based induction chemotherapy in patients with locally advanced squamous cell carcinoma of the head and neck: the Dana Farber Cancer Institute experience publication-title: Cancer – volume: 123 start-page: 372 year: 2008 end-page: 379 article-title: miR‐15b and miR‐16 modulate multidrug resistance by targeting BCL2 in human gastric cancer cells publication-title: Int J Cancer – volume: 9 start-page: 189 year: 2006 end-page: 198 article-title: Unique microRNA molecular profiles in lung cancer diagnosis and prognosis publication-title: Cancer Cell – volume: 55 start-page: 74 year: 2005 end-page: 108 article-title: Global cancer statistics, 2002 publication-title: CA Cancer J Clin – volume: 12 start-page: 155 year: 1993 end-page: 170 article-title: Glutathione‐related enzymes, glutathione and multidrug resistance publication-title: Cytotechnology – volume: 270 start-page: 31269 year: 1995 end-page: 31275 article-title: Altered expression of M beta 2, the class II beta‐tubulin isotype, in a murine J774.2 cell line with a high level of taxol resistance publication-title: J Biol Chem – volume: 71 start-page: 537 year: 2002 end-page: 592 article-title: Mammalian ABC transporters in health and disease publication-title: Annu Rev Biochem – volume: 68 start-page: 425 year: 2008 end-page: 433 article-title: MicroRNA expression profiling in human ovarian cancer: miR‐214 induces cell survival and cisplatin resistance by targeting PTEN publication-title: Cancer Res – volume: 34 start-page: 505 year: 2008 end-page: 520 article-title: Combined action and regulation of phase II enzymes and multidrug resistance proteins in multidrug resistance in cancer publication-title: Cancer Treat Rev – volume: 9 start-page: 1557 year: 2003 end-page: 1565 article-title: Low‐dose fractionated radiation potentiates the effects of paclitaxel in wild‐type and mutant p53 head and neck tumor cell lines publication-title: Clin Cancer Res – volume: 53 start-page: 747 year: 1993 end-page: 754 article-title: How cancer cells evade chemotherapy: sixteenth Richard and Hinda Rosenthal Foundation Award Lecture publication-title: Cancer Res – volume: 5 start-page: 251 year: 2005 end-page: 265 article-title: Cisplatin is a DNA‐damaging antitumour compound triggering multifactorial biochemical responses in cancer cells: importance of apoptotic pathways publication-title: Curr Med Chem Anticancer Agents – volume: 88 start-page: 11 year: 2003 end-page: 17 article-title: Docetaxel induction therapy in locally advanced squamous cell carcinoma of the head and neck publication-title: Br J Cancer – volume: 36 start-page: 2891 year: 1976 end-page: 2895 article-title: Effect of adriamycin on DNA, RNA and protein synthesis in cell‐free systems and intact cells publication-title: Cancer Res – volume: 76 start-page: 582 year: 2008 end-page: 588 article-title: Role of microRNA miR‐27a and miR‐451 in the regulation of MDR1/P‐glycoprotein expression in human cancer cells publication-title: Biochem Pharmacol – volume: 34 start-page: 397 year: 1994 end-page: 419 article-title: The methotrexate story: a paradigm for development of cancer chemotherapeutic agents publication-title: Adv Enzyme Regul – volume: 12 start-page: 19 issue: 10 Suppl 7 year: 1998 end-page: 22 article-title: Infusional 5‐FU: historical evolution, rationale, and clinical experience publication-title: Oncology (Williston Park) – volume: 5 start-page: 495 year: 1994 end-page: 505 article-title: Paclitaxel (Taxol) and docetaxel (Taxotere): not simply two of a kind publication-title: Ann Oncol – volume: 14 start-page: 35 issue: Suppl 1 year: 2005 end-page: 48 article-title: Mechanisms of drug resistance in cancer chemotherapy publication-title: Med Princ Pract – volume: 345 start-page: 1890 year: 2001 end-page: 1900 article-title: Head and neck cancer publication-title: N Engl J Med – volume: 5 start-page: 536 year: 2006 end-page: 543 article-title: Chemosensitizing multiple drug resistance of human carcinoma by Bicyclol involves attenuated p‐glycoprotein, GST‐P and Bcl‐2 publication-title: Cancer Biol Ther – volume: 102 start-page: 19075 year: 2005 end-page: 19080 article-title: The role of microRNA genes in papillary thyroid carcinoma publication-title: Proc Natl Acad Sci U S A – volume: 2 start-page: 48 year: 2002 end-page: 58 article-title: Multidrug resistance in cancer: role of ATP‐dependent transporters publication-title: Nat Rev Cancer – volume: 22 start-page: 1844 year: 2002 end-page: 1857 article-title: Precipitous release of methyl‐CpG binding protein 2 and histone deacetylase 1 from the methylated human multidrug resistance gene (MDR1) on activation publication-title: Mol Cell Biol – volume: 146 start-page: 195 year: 1999 end-page: 199 article-title: Amplification of the mdr1‐gene is uncommon in recurrent ovarian carcinomas publication-title: Cancer Lett – ident: e_1_2_6_17_2 doi: 10.1261/rna.2183803 – ident: e_1_2_6_12_2 doi: 10.2174/1381612043453117 – ident: e_1_2_6_30_2 doi: 10.2174/1568009054863609 – ident: e_1_2_6_16_2 doi: 10.1126/science.1064921 – volume: 12 start-page: 19 issue: 10 year: 1998 ident: e_1_2_6_24_2 article-title: Infusional 5‐FU: historical evolution, rationale, and clinical experience publication-title: Oncology (Williston Park) contributor: fullname: Lokich J – ident: e_1_2_6_13_2 doi: 10.4161/cbt.5.5.2655 – ident: e_1_2_6_27_2 doi: 10.1016/S0304-3835(99)00263-3 – volume: 36 start-page: 2891 year: 1976 ident: e_1_2_6_23_2 article-title: Effect of adriamycin on DNA, RNA and protein synthesis in cell‐free systems and intact cells publication-title: Cancer Res contributor: fullname: Momparler RL – ident: e_1_2_6_29_2 doi: 10.1038/sj.onc.1210681 – ident: e_1_2_6_11_2 doi: 10.1159/000086183 – ident: e_1_2_6_3_2 doi: 10.1056/NEJMra001375 – ident: e_1_2_6_18_2 doi: 10.1016/j.ccr.2006.01.025 – ident: e_1_2_6_5_2 doi: 10.1038/sj.bjc.6600685 – ident: e_1_2_6_32_2 doi: 10.1016/j.bcp.2008.06.007 – ident: e_1_2_6_28_2 doi: 10.1074/jbc.270.52.31269 – ident: e_1_2_6_2_2 doi: 10.3322/canjclin.55.2.74 – volume: 9 start-page: 1557 year: 2003 ident: e_1_2_6_14_2 article-title: Low‐dose fractionated radiation potentiates the effects of paclitaxel in wild‐type and mutant p53 head and neck tumor cell lines publication-title: Clin Cancer Res contributor: fullname: Dey S – ident: e_1_2_6_4_2 doi: 10.1002/cncr.11063 – ident: e_1_2_6_7_2 doi: 10.1146/annurev.biochem.71.102301.093055 – ident: e_1_2_6_10_2 doi: 10.1128/MCB.22.6.1844-1857.2002 – ident: e_1_2_6_20_2 doi: 10.1073/pnas.0509603102 – ident: e_1_2_6_15_2 doi: 10.1002/1097-0215(200102)9999:9999<::AID-IJC1180>3.0.CO;2-T – ident: e_1_2_6_33_2 doi: 10.1002/ijc.23501 – ident: e_1_2_6_26_2 doi: 10.2174/1568011053765967 – volume: 53 start-page: 747 year: 1993 ident: e_1_2_6_22_2 article-title: How cancer cells evade chemotherapy: sixteenth Richard and Hinda Rosenthal Foundation Award Lecture publication-title: Cancer Res contributor: fullname: Gottesman MM – ident: e_1_2_6_9_2 doi: 10.1007/BF00744663 – ident: e_1_2_6_31_2 doi: 10.1158/0008-5472.CAN-07-2488 – ident: e_1_2_6_6_2 doi: 10.1016/j.ctrv.2008.03.002 – ident: e_1_2_6_25_2 doi: 10.1016/0065-2571(94)90025-6 – ident: e_1_2_6_8_2 doi: 10.1038/nrc706 – ident: e_1_2_6_21_2 doi: 10.1093/oxfordjournals.annonc.a058903 – ident: e_1_2_6_19_2 doi: 10.1158/0008-5472.CAN-05-1783 |
SSID | ssj0003642 |
Score | 2.3213964 |
Snippet | Background
The purpose of this study was to investigate the potential role of variable microRNA (miRNA) expression in the development of multidrug resistance... The purpose of this study was to investigate the potential role of variable microRNA (miRNA) expression in the development of multidrug resistance (MDR) in... Abstract Background The purpose of this study was to investigate the potential role of variable microRNA (miRNA) expression in the development of multidrug... Background The purpose of this study was to investigate the potential role of variable microRNA (miRNA) expression in the development of multidrug resistance... BACKGROUNDThe purpose of this study was to investigate the potential role of variable microRNA (miRNA) expression in the development of multidrug resistance... |
SourceID | proquest crossref pubmed pascalfrancis wiley istex |
SourceType | Aggregation Database Index Database Publisher |
StartPage | 786 |
SubjectTerms | 5-Fluorouracil Antineoplastic Agents - pharmacology Biological and medical sciences cancer Carcinoma - drug therapy Carcinoma - genetics Carcinoma, Squamous Cell Cell Line, Tumor - drug effects Docetaxel Drug Resistance, Multiple - genetics Drug Resistance, Neoplasm - genetics Gene Expression Regulation, Neoplastic head and neck Head and Neck Neoplasms - drug therapy Head and Neck Neoplasms - genetics Humans Medical sciences micro-RNA MicroRNAs - genetics multidrug resistance Neoplasms, Squamous Cell - drug therapy Neoplasms, Squamous Cell - genetics Otorhinolaryngology (head neck, general aspects and miscellaneous) Otorhinolaryngology. Stomatology Pharmacogenetics Reverse Transcriptase Polymerase Chain Reaction Sensitivity and Specificity Squamous Cell Carcinoma of Head and Neck Taxoids - pharmacology Tumors |
Title | MicroRNA expression profiles of head and neck squamous cell carcinoma with docetaxel-induced multidrug resistance |
URI | https://api.istex.fr/ark:/67375/WNG-GBX0QS8Z-J/fulltext.pdf https://onlinelibrary.wiley.com/doi/abs/10.1002%2Fhed.21540 https://www.ncbi.nlm.nih.gov/pubmed/21560177 https://search.proquest.com/docview/1468353514 https://search.proquest.com/docview/866250011 |
Volume | 33 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9NAEB5V7YULD_FyKdWCEOLi1Pba67V6KvQRVWokChURQrL2ZUChDsSJFPXUn8Bv5Jcws44TBVEJcfNhbWtnZ3a-nZ35BuBFFtlCqCwPk0LokPIuQlUJExYuToRF85M51TufDUT_Ij0dZsMN2O9qYVp-iGXAjSzD79dk4Eo3eyvS0C_O9tBfpXRej3lO6VyH5yvqKC7S9qYz5RRfSTtWoSjZW7655ou2SKxzyo1UDYqnavta_A14ruNY74iO78Cnbgpt_smoN5vqnrn6g93xP-d4F24vACo7aDXqHmy4-j40Z5S3dz44YG6-yJyt2aLdd8PGFcMt3TJVW1Y7M2LNj5mikAKjawFmqF1RPb5UjIK-zKLHnKq5-_br-ufX2qJqWebTGu1k9pnhxwnRoio-gIvjo_dv-uGiXUNo0PCjsDBowZUtnMuSzLlKxyYzMaebQak0z1WlBaIvW8mEa66UrGg7yIUoEJVwI_lD2KzHtXsMTNpYizz3ZIOpiwvtsshJ6XLFjY6MC-B5t3Dl95aVo2z5l5MSZVZ6mQXw0i_pcoSajCiNLc_KD4OT8uT1MHr7Tn4sTwPYXVvz5QuIbiRRWwTwrFOCEq2PZKdqh2KkgxNCWKqGCIDdMEYKPGMS9A7gUatAqx9QHTvKIIBXXg1unkzZPzr0D9v_PvQJ3Goj4BQz2oHN6WTmniKEmupdbyu_ASHxF5A |
link.rule.ids | 315,783,787,1378,27938,27939,46308,46732 |
linkProvider | Wiley-Blackwell |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9NAEB5V7QEuPMTLPMqCEOLi1Pba67XEpdBHKE0kSiuiSmi1LwMKOJCHFHHiJ_Ab-SXM2HGiICohbj6sbe3szM63szPfADzJIlcIneVhUggTUt5FqEthw8LHiXBofjKneudeX3TP0qNBNtiA520tTMMPsQy4kWXU-zUZOAWkd1asoR-966DDSvHAvoXmzql_wd7JijyKi7S560w5RVjSllcoSnaWr655oy0S7JyyI_UEBVQ2nS3-Bj3XkWztig6uwvt2Ek0GyrAzm5qO_f4Hv-P_zvIaXFlgVLbbKNV12PDVDZj0KHXvpL_L_HyRPFuxRcfvCRuVDHd1x3TlWOXtkE2-zTRFFRjdDDBLHYuq0RfNKO7LHDrNqZ77z79-_PxUOdQux-rMRjeefWD4cQK1qI034exg__RlN1x0bAgt2n4UFhaNuHSF91mSeV-a2GY25nQ5KLXhuS6NQADmSplww7WWJe0IuRAFAhNuJb8Fm9Wo8neASRcbkec132Dq48L4LPJS-lxzayLrA3jcrpz62hBzqIaCOVEoM1XLLICn9ZouR-jxkDLZ8ky96x-qwxeD6M1bea6OAtheW_TlCwhwJLFbBPCo1QKFBkiy05VHMdLZCVEsFUQEwC4YIwUeMwl9B3C70aDVD6iUHWUQwLNaDy6ejOru79UPd_996EO41D3tHavjV_3X9-ByExCnENJ92JyOZ_4BIqqp2a4N5zd7WBuq |
linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwEB5VrYS48BCvUCgGIcQl2yROHEecCtvtUugKChWrCsnyKxQtZMs-pBUnfgK_kV_CTLIPLaIS4paDk8jjGc_n8cw3AI-zyBVCZ3mYFMKElHcR6lLYsPBxIhyan8yp3vmoJ7on6WE_62_As0UtTMMPsQy4kWXU-zUZ-Lkrd1ekoWfetdBfpXhe30oFjyifq3284o7iIm2uOlNOAZZ0QSsUJbvLV9ec0RbJdUbJkXqM8imbxhZ_Q57rQLb2RJ2r8HExhyYBZdCaTkzLfv-D3vE_J3kNrswRKttrVOo6bPjqBoyPKHHvuLfH_GyeOluxeb_vMRuWDPd0x3TlWOXtgI2_TTXFFBjdCzBL_Yqq4VfNKOrLHLrMiZ75L79-_PxcOdQtx-q8RjeafmL4cYK0qIs34aSz__5FN5z3awgtWn4UFhZNuHSF91mSeV-a2GY25nQ1KLXhuS6NQPjlSplww7WWJe0HuRAFwhJuJb8Fm9Ww8neASRcbkec122Dq48L4LPJS-lxzayLrA3i0WDh13tByqIaAOVEoM1XLLIAn9ZIuR-jRgPLY8kx96B2og-f96O07eaoOA9hZW_PlCwhvJHFbBPBwoQQKzY9kpyuPYqSTE2JYKocIgF0wRgo8ZBL2DuB2o0CrH1AhO8oggKe1Glw8GdXdb9cPd_996AO49KbdUa9f9l5tw-UmGk7xo3uwORlN_X2EUxOzU5vNbxwJGlk |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=MicroRNA+expression+profiles+of+head+and+neck+squamous+cell+carcinoma+with+docetaxel-induced+multidrug+resistance&rft.jtitle=Head+%26+neck&rft.au=Dai%2C+Yuemeng&rft.au=Xie%2C+Cheng-hui&rft.au=Neisiv%2C+John+P&rft.au=Fan%2C+Chun-Yang&rft.date=2011-06-01&rft.issn=1097-0347&rft.volume=33&rft.issue=6&rft.spage=786&rft.epage=791&rft_id=info:doi/10.1002%2Fhed.21540&rft.externalDBID=NO_FULL_TEXT |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1043-3074&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1043-3074&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1043-3074&client=summon |